Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic and Wegovy are both semaglutide medications, but they carry different FDA approvals and serve different patient populations. Ozempic received FDA clearance in 2017 specifically for lowering blood sugar in adults with type 2 diabetes, while Wegovy earned FDA approval in 2021 as a dedicated weight management treatment. Understanding this distinction helps patients and clinicians choose the right medication pathway.
FDA Approval Status: Ozempic vs. Wegovy Explained
Ozempic is an FDA-approved diabetes medication containing semaglutide at a standard concentration formulated for glycemic control. The Food and Drug Administration cleared Ozempic based on clinical trials demonstrating its ability to reduce HbA1c levels and lower cardiovascular risk in type 2 diabetes patients. While weight loss is a documented side effect of Ozempic in diabetes trials, the medication was not developed or approved with obesity as its primary indication.
Wegovy is the FDA-approved alternative specifically designed for chronic weight management in adults with obesity or overweight status with weight-related conditions. The regulatory path for Wegovy involved separate clinical trials focused on weight loss as the primary outcome, leading to distinct dosing schedules and labeling compared to Ozempic. This distinction matters for insurance coverage, prescribing authority, and patient expectations about the medication's intended use.
How Semaglutide Works for Weight Loss at the Cellular Level
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that signals fullness and regulates appetite in the brain's hypothalamus. The medication activates GLP-1 receptors, slowing gastric emptying and reducing hunger signals while increasing feelings of satiety after meals. This mechanism leads to spontaneous calorie reduction without requiring sustained willpower, explaining why patients often report diminished cravings and portion sizes.
Clinical trials show that semaglutide produces dose-dependent weight loss, with participants losing 10-15% of baseline body weight at standard therapeutic doses over 68 weeks. The effect is sustained as long as patients continue the medication; discontinuation typically results in weight regain. Beyond appetite suppression, semaglutide also improves insulin sensitivity and may reduce cardiovascular inflammation markers in overweight populations.
Compounded Semaglutide as an Alternative to Brand-Name Medications
Compounded semaglutide prepared by licensed 503A compounding pharmacies provides patients with a cost-effective pathway to GLP-1 therapy without the premium pricing of brand medications. PlexusDx partners exclusively with licensed 503A compounding pharmacies—facilities meeting stringent federal oversight—to prepare customized semaglutide formulations. Compounded medications are not FDA-approved in the traditional sense but are legally manufactured under the 503A exemption for personalized pharmacy preparation.
PlexusDx's Compounded Semaglutide Injection starts at $149 per month with no insurance requirement, HSA/FSA eligibility, and consistent pricing across all dose levels. Patients receive the same active pharmaceutical ingredient as Ozempic or Wegovy—semaglutide—with the flexibility to titrate doses under medical supervision. This approach removes barriers like prior authorization delays and high copays while maintaining clinical safety through pharmacist oversight and physician monitoring.
Personalized Dosing and the Role of Genetic Testing in GLP-1 Response
Individual response to semaglutide varies significantly based on genetic factors affecting peptide hormone pathways and metabolic regulation. PlexusDx's Precision Peptide Genetic Test identifies key variants including GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609—genetic markers associated with GLP-1 responsiveness and weight loss potential. This testing maps 14 distinct metabolic pathways and 49 peptide-related genes, providing actionable insights that guide initial dosing strategy and medication selection.
Patients with favorable genetic profiles in GLP-1 and GIPR pathways often experience stronger appetite suppression at lower doses, while those with alternative variants may require progressive titration to achieve target weight loss. The Precision Peptide Genetic Test costs $99 as an add-on after the first month of treatment, allowing PlexusDx to establish baseline response before offering personalized optimization. This precision medicine approach reduces trial-and-error dosing and maximizes efficacy for each patient's unique biochemistry.
Common Concerns About Compounded Medications and Safety Standards
Patients often worry whether compounded semaglutide meets safety standards equivalent to FDA-approved brand versions. Licensed 503A compounding pharmacies operate under strict federal regulations including sterility testing, potency verification, and contamination screening. The U.S. Pharmacopeial Convention (USP) sets standards for compounded medications, and PlexusDx's partner pharmacies maintain comprehensive quality assurance protocols that exceed minimum requirements.
Compounded semaglutide carries the same side effect profile as brand Ozempic and Wegovy—nausea, vomiting, constipation, and appetite changes are expected during dose titration. The key difference is accessibility: compounded options remove financial and bureaucratic barriers while delivering identical active ingredients. PlexusDx provides physician oversight, medication counseling, and side effect management to ensure safe, supervised treatment regardless of formulation source.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic FDA-approved for weight loss, or only for diabetes?
Ozempic carries FDA approval exclusively for type 2 diabetes management, not weight loss. Wegovy is the FDA-approved semaglutide formulation designed specifically for obesity treatment. However, semaglutide reliably produces weight loss in both diabetes and non-diabetes patients through its GLP-1 receptor activation mechanism.
Does compounded semaglutide work the same as Ozempic or Wegovy?
Compounded semaglutide contains the identical active pharmaceutical ingredient and produces equivalent weight loss and appetite suppression as brand medications. The difference lies in manufacturing (licensed pharmacy versus pharmaceutical company) and cost: PlexusDx's Compounded Semaglutide Injection starts at $149/mo compared to brand prices exceeding $900/mo, with no insurance requirement or membership fee.
How much does semaglutide cost through PlexusDx?
PlexusDx's Compounded Semaglutide Injection starts at $149 per month with flat pricing across all dose levels—your dose may need to go up, but your price won't. The medication is HSA/FSA eligible, available in all 50 states, and requires no insurance or subscription commitment.
What are the most common side effects of semaglutide for weight loss?
Nausea, vomiting, constipation, and reduced appetite are typical during the first 2-4 weeks as the body adjusts to GLP-1 activation. Most side effects resolve within days to weeks; taking injections with food, staying hydrated, and slow dose escalation reduce severity. Serious complications like pancreatitis are rare but require immediate medical attention if abdominal pain develops.
How does the Precision Peptide Genetic Test help optimize my semaglutide dose?
PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, MC4R, and FTO genes that predict your individual response to semaglutide and weight loss capacity. Results guide initial dosing strategy and help identify whether you may need faster titration or alternative dual-compound options like GLP-Squared, maximizing efficacy based on your unique genetics.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Ozempic vs Wegovy Which Is More Effective for Weight Loss
How to Wean Off Ozempic for Weight Loss: A Comprehensive Guide